[Secondary prevention of cerebral infarction caused by atherosclerosis. 3-year comparison of flurbiprofen and an ergot derivative].
A multicentre controlled trial was conducted on 383 patients to compare the effectiveness of flurbiprofen (100 mg/day) and an ergot derivative in preventing cerebral infarction. The end-point of the trial was recurrence within 3 years of treatment with one or the other drug of a fatal or non-fatal cerebral infarction. Only those patients who had already experienced an established and disabling ischaemic accident in the carotid or vertebro-basilar territory were included; 88% of these entered the trial less than 6 weeks after the accident. Sixty-one patients had recurrent cerebral infarction during the 3-year observation period: 22 in the flurbiprofen group and 39 in the ergot derivative group (p less than 0.02 log rank test adjusted by centre). The actuarial recurrence rates in the two groups were 13% and 21% respectively. These results concur with those of other trials involving aspirin to demonstrate the value of antiplatelet aggregation drugs in the secondary prevention of atherothrombotic cerebral infarction.
D001161:Arteriosclerosis / Q000150:complications* / Q000188:drug therapy; D002544:Cerebral Infarction / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004876:Ergot Alkaloids / Q000627:therapeutic use*; D005260:Female; D005480:Flurbiprofen / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D011422:Propionates / Q000627:therapeutic use*; D012008:Recurrence
D004876:Ergot Alkaloids; D011422:Propionates; D005480:Flurbiprofen
Prévention secondaire des infarctus cérébraux dus à l'athérosclérose. Comparaison à trois ans du flurbiproféne et d'un dérivé de l'ergot de seigle.